On June 5, 2017 Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient’s immune system against cancer, reported that it presented a poster from the Phase 2 trial evaluating HS-410 (vesigenurtacel-L) in combination with standard of care, Bacillus Calmette-Guérin (BCG), in the treatment of non-muscle invasive bladder cancer at the 2017 ASCO (Free ASCO Whitepaper) (American Association of Clinical Oncologists) Annual Meeting in Chicago yesterday (Press release, Heat Biologics, JUN 5, 2017, View Source [SID1234519384]). Schedule your 30 min Free 1stOncology Demo! Study findings suggest that immune response activity, as measured by ELISPOT analysis on peripheral blood lymphocytes drawn from low-dose HS-410 patients over the course of their treatment, demonstrates a substantially better recurrence free survival outcome than BCG alone. In the trial, 100% of the patients who showed a positive ELISPOT immune response to the low-dose therapy remained disease-free after 18 months. This data compares favorably to the 80% disease-free rate in the placebo arm and is consistent with data reported in March for our lung cancer trial where 100% of the patients with positive clinical positive clinical benefit and tumor reduction also showed positive ELISPOT immune response to HS-110.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Jeff Hutchins, Ph.D., Heat’s Chief Scientific Officer and Senior Vice President of Preclinical Development, commented, "We are encouraged by the findings of this study as the data continues to mature, which gives us further confidence in the ability of our approach to mount an immune response and protect patients as part of a combination approach in immunotherapy. We look forward to continuing to progress our HS-110 in combination with Bristol-Myers Squibb’s checkpoint inhibitor nivolumab in lung cancer."
As previously announced, the Company discontinued its HS-410 program in order to focus on current and future checkpoint and T cell co-stimulator combination programs, including its HS-110 Phase 2 lung cancer program in combination with Bristol-Myers Squibb’s checkpoint inhibitor nivolumab in lung cancer.